Healthcare's Deal Surge: $106 Billion by June and a Medtech Reshaping
Healthcare is running the strongest deal market since 2019. Biopharma M&A passed $106 billion by early June and is tracking toward $250 billion for the year; one late-March stretch produced seven billion-dollar-plus deals in twelve days. Medtech added $36.5 billion in the first half. The headlines are familiar by now - Abbott's $21 billion acquisition of Exact Sciences, Boston Scientific's $14.5 billion agreement for Penumbra, Danaher's $9.9 billion all-cash offer for Masimo, and the $18.3 billion take-private of Hologic by Blackstone and TPG.
Portfolio reshaping, not empire building
What distinguishes this cycle is discipline. Large strategics are simultaneously divesting non-core units and paying premiums in chosen categories - cardiovascular, neurostimulation, connected devices, patient monitoring and workflow software. That divest-and-double-down pattern creates two distinct mid-market opportunities: carve-out acquisitions for ambitious buyers, and strategic exits at category-leader prices for focused sellers.
The middle market is private equity's territory
In healthcare services, private equity now accounts for more than 40% of middle-market deal volume, executing platform-and-add-on strategies across care services, pharma services and healthcare IT. First-quarter services deal value reached roughly $18 billion. For founder-owned clinics groups, CDMOs and service providers, this means the most probable buyer is a sponsor-backed platform with a build thesis - a buyer type that values integration readiness as highly as EBITDA.
Valuation implications
- Segment beats size. A €30 million monitoring-technology business in a favoured category can outprice a €100 million generalist.
- Regulatory readiness is priced. Clean quality systems and audit history remove the discount buyers otherwise apply reflexively.
- Reimbursement clarity de-risks the model. Buyers pay for revenue whose payer logic they can underwrite.
Sellers entering this market meet sophisticated, well-capitalised buyers with clear theses. The preparation standard has risen accordingly - and so have the rewards for meeting it.
"Healthcare buyers are not buying revenue this year. They are buying category leadership in the segments they have decided to own."
Charlotte Meyer, Partner, Valuation & AnalyticsOperating in MedTech or care services? The wave is here.
Charlotte's team values healthcare businesses the way this year's buyers do - segment by segment.